Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N8-acetylspermidine is a naturally occurring acetylated derivative of the polyamine spermidine, produced through both endogenous metabolic pathways and microbial activity in the gut. It has emerged as a significant bioactive metabolite in the context of intestinal homeostasis and inflammatory regulation. Research, particularly involving natural products like lily polysaccharides, has demonstrated that N8-acetylspermidine acts as a key signaling molecule that modulates the cGAS-STING (cyclic GMP-AMP synthase - stimulator of interferon genes) axis. By inhibiting this pathway, N8-acetylspermidine suppresses the production of pro-inflammatory cytokines and alleviates symptoms of colitis. While currently in the preclinical research stage, it represents a potential therapeutic lead or biomarker for inflammatory bowel diseases (IBD), including ulcerative colitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N8-acetylspermidine.